Epiretinal brachytherapy for wet AMD gets NICE thumbs down
This article was originally published in Clinica
Epiretinal brachytherapy for treating wet age-related macular degeneration (AMD) should only be used in the context of research, the UK’s National Institute for Health and Clinical Excellence (NICE) has said. In guidance issued today under its interventional procedures programme, NICE cited safety concerns raised by the technique and the need for better evidence on its effectiveness.
You may also be interested in...
The Swiss biotech's focal-onset seizure therapy, which is licensed from South Korea's SK and is already approved in the US, could have potential in indications beyond epilepsy, Arvelle's CEO tells Scrip.
Biocon has reported FDA clearance for its Malaysian insulin facility, while Lupin and Xellia have also received plant approvals. Meanwhile, Alembic has seen mixed fortunes, receiving both Form 483 observations and an EIR.
Lannett has begun marketing a US rival to Adderall XR through a partnership with Elite and SunGen. But the product will face competition from a range of other generics.